about
Evaluation of disease-free survival as an intermediate metric of overall survival in patients with localized renal cell carcinoma: A trial-level meta-analysis.Variation in the use of active surveillance for low-risk prostate cancer.Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma.Apatorsen plus docetaxel versus docetaxel alone in platinum-resistant metastatic urothelial carcinoma (Borealis-2).Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortiumMechanisms of acquired resistance to rapalogs in metastatic renal cell carcinomaThe influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization studyA GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosisTargeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinomaSafety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinomaMetabolomic adaptations and correlates of survival to immune checkpoint blockadeSafety and efficacy of immune checkpoint inhibitors in advanced urological cancers with pre-existing autoimmune disorders: a retrospective international multicenter studyConditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitorsOutcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinomaEverolimus and pazopanib (E/P) benefit genomically selected patients with metastatic urothelial carcinomaEvaluating a Video-Based, Personalized Webpage in Genitourinary Oncology Clinical Trials: A Phase 2 Randomized TrialA model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinomaIL-8 and cancer prognosis on immunotherapyInterplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinomaSafety and efficacy of CDX-014, an antibody-drug conjugate directed against T cell immunoglobulin mucin-1 in advanced renal cell carcinoma
P50
Q47269814-5A5FA578-5F1E-4F1A-85D6-34084219930BQ47809867-86BFB357-F350-45EB-9330-BFC71840BC18Q48307020-7648FA1E-4218-4D9C-86EE-7FE728EF3242Q53681746-2FA62167-C483-477F-A755-BFF2F5C9E48AQ57279960-7D820117-0235-4AE0-BB03-54193BBD720BQ58693750-39B7B21E-5256-4F0E-94A2-15210864F432Q60921979-0C32E161-5484-4569-8867-CB6AD64E20B1Q64067743-2B4D6530-E76F-49B6-9F97-2EA81ADB514DQ88414624-6FD9058F-0891-4DC0-9773-BD53F6BFC464Q89747242-9B554670-A5FE-4520-BE67-A37B230F860DQ90287976-369D4716-55DF-48DA-BFD5-707228B58A5AQ90690141-88F0DC79-4E6E-496D-AF6C-1267DE8800CBQ90803091-721FABCD-DB42-4F0F-8F08-5C33142F9302Q91347054-753044AB-FB41-42E9-8E72-37E3425A50B9Q91472224-CEA447C0-AA3E-450E-857D-152F0166077CQ91690734-05E11EF7-C511-4E68-9C02-F17F1FA5A9FEQ92133160-B977F93D-920F-4879-A4CB-DD961226716CQ94671897-E17359C8-ED84-4826-B668-15C3B6D15499Q96023037-5205E5E7-CCA1-446A-9DBE-86387EDA3DCEQ96023763-105724E7-D68D-42F0-9FD6-45BE378C9E94
P50
description
researcher
@en
wetenschapper
@nl
name
Toni K Choueiri
@en
Toni K Choueiri
@nl
type
label
Toni K Choueiri
@en
Toni K Choueiri
@nl
prefLabel
Toni K Choueiri
@en
Toni K Choueiri
@nl
P31
P496
0000-0002-9201-3217